Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Meta Expands AI Training With Employee Activity Tracking Tools 
ATLANTA, March 07, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota’s CEO & President Joseph Patti, PhD will present a corporate overview at the 28th Annual ROTH Conference on Monday, March 14, 2016 at 12:00 p.m. PT in Dana Point, CA.
A live webcast of the presentation can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.biotapharma.com or at http://wsw.com/webcast/roth30/bota.
A replay of the webcast will be archived for 30 days following the presentation.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections and has received Fast Track designation by the U.S. FDA; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals, Inc.
Mark Colonnese Executive Vice President and Chief Financial Officer (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
